| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, November 12, 2026, at 4:30 p.m. ET |
| 04 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
–Existing $400 million facility prepaid at a $68 million discount to the contractual minimum repayment amount |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, August 4, 2026 at 4:30 p.m. ET |
| 16 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the “Company”) appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026. |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, May 7, 2026 at 4:30 p.m. ET |
| 20 Mar 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The following proposals were submitted to the stockholders of Arrowhead Pharmaceuticals, Inc. (the “Company”) at the 2026 Annual Meeting of Stockholders held on March 19, 2026: |
| 05 Feb 2026 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, February 5, 2026 at 4:30 p.m. ET |
| 12 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
FIRST SUPPLEMENTAL INDENTURE, dated as of January 12, 2026, between Arrowhead Pharmaceuticals, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), to the... |
| 09 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) $625,000,000 principal amount of its 0% Convertible Se... |
| 06 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
Obesity KOL Webinar ARO-INHBE and ARO-ALK7 Interim Phase 1/2a Clinical Data January 06, 2026 |
| 25 Nov 2025 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, November 25, 2025 at 4:30 p.m. ET |
| 18 Nov 2025 |
8-K: Other Events
REDEMPLO® (plozasiran) FDA Approval Conference Call November 18, 2025 |
| 12 Sep 2025 |
8-K: Other Events
COMPLAINT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 UMHOFER, MITCHELL & KING LLP Matthew Donald Umhofer (SBN 206607) Margaret E. Dayton (SBN 274353) 767 S. Alameda St., Suite 270 Los Angeles, CA 90021 Tel... |
| 11 Sep 2025 |
8-K: Other Events
1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE ARROWHEAD PHARMACEUTICALS, INC., Plaintiff, v. IONIS PHARMACEUTICALS, INC., Defendant. C.A. No.________ JURY TRIAL DEMANDED PLAINTIFF’S COMPLAINT FOR DECLARATORY JUDGMENT... |
| 02 Sep 2025 |
8-K: Entry into a Material Definitive Agreement
–Upon closing, Arrowhead will receive an upfront payment of $200 million |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, August 7, 2025 at 4:30 p.m. ET |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, May 12, 2025 at 4:30 p.m. ET |
| 15 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
PASADENA, Calif., Apr. 15, 2025 — Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead’s Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and ... |
| 19 Mar 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The following proposals were submitted to the stockholders of Arrowhead Pharmaceuticals, Inc. (the “Company”) at the 2025 Annual Meeting of Stockholders held on March 12, 2025: |
| 10 Feb 2025 |
8-K: Results of Operations and Financial Condition
Conference Call and Webcast Today, February 10, 2025 at 4:30 p.m. ET |
Loading...